Your browser doesn't support javascript.
loading
The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients.
Guler, O C; Engels, B; Onal, C; Everaert, H; Van den Begin, R; Gevaert, T; de Ridder, M.
Afiliação
  • Guler OC; Department of Radiation Oncology, Faculty of Medicine, Karadeniz Technical University, Trabzon, 61080, Turkey. ocguler@gmail.com.
  • Engels B; Department of Radiotherapy, UZ Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, B-1090 , Brussels, Belgium.
  • Onal C; Department of Radiation Oncology, Faculty of Medicine, Baskent University, Adana, Turkey.
  • Everaert H; Department of Nuclear Medicine, UZ Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, B-1090 , Brussels, Belgium.
  • Van den Begin R; Department of Radiotherapy, UZ Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, B-1090 , Brussels, Belgium.
  • Gevaert T; Department of Radiotherapy, UZ Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, B-1090 , Brussels, Belgium.
  • de Ridder M; Department of Radiotherapy, UZ Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, B-1090 , Brussels, Belgium.
Clin Transl Oncol ; 20(4): 484-490, 2018 Apr.
Article em En | MEDLINE | ID: mdl-28795303
BACKGROUND: To investigate the efficacy and toxicity of 68Ga-PSMA-HBED-CC (68Ga-PSMA) PET-CT-guided RT in the treatment of oligometastatic prostate cancer retrospectively. METHODS: A total of 23 prostate cancer patients with biochemical relapse, of which 13 were castration sensitive (CS) and 10 castration resistant (CR), were treated with intensity-modulated and image-guided RT (IMRT-IGRT) on ≤3 metastases detected by 68Ga PSMA PET-CT. Androgen deprivation therapy was continued in CR patients. RESULTS: A total of 38 metastases were treated. The involved sites were pelvic bone (n = 16), pelvic lymph nodes (n = 11), paraaortic lymph nodes (n = 6), ribs (n = 3) and vertebral body (n = 2). The median PSA prior to RT was 1.1 ng/mL (range 0.1-29.0 ng/mL). A median dose of 43.5 Gy (range 30-64 Gy) was delivered by IMRT-IGRT in 12-27 fractions. At a median follow-up of 7 months (range 2-17 months), 19 patients (83%) were in remission. Four patients (17%) developed distant recurrences. The actuarial 1-year LC, PFS and OS rates were 100, 51 (95% CI 8-83%) and 100%. Univariate analysis demonstrated a statistically significantly better PFS in CS patients as compared to CR patients (1-year PFS 67 vs. 0%, p < 0.01). One patient experienced grade 2 acute gastrointestinal toxicity. Grade 3 or more toxicity events were not observed. CONCLUSIONS: By providing optimal LC, low toxicity and a promising PFS in CS patients, the current retrospective study illustrated that 68Ga PSMA PET-CT-guided RT may be an attractive treatment strategy in patients with oligometastatic prostate cancer. Validation by randomized trials is eagerly awaited.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Radioterapia Guiada por Imagem / Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada / Metástase Neoplásica Tipo de estudo: Observational_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Turquia País de publicação: Itália
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Radioterapia Guiada por Imagem / Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada / Metástase Neoplásica Tipo de estudo: Observational_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Turquia País de publicação: Itália